Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

14.97 -0.59 (-3.79%)

Streaming Delayed Price Updated: 12:15 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

35 36 Next >

Is Sarepta Therapeutics Stock a Bad-News Buy? ↗

November 09, 2023

Analysts still expect some sizable returns from the stock.

Via The Motley Fool

1 Gene Therapy Stock to Buy and Hold for the Long Haul ↗

November 08, 2023

The biotech has what it takes to overcome recent obstacles.

Via The Motley Fool

Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks? ↗

November 08, 2023

Just because a stock is "on sale" doesn't inherently make it worth purchasing.

Via The Motley Fool

SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

November 07, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

8 Health Care Stocks Whale Activity In Today's Session ↗

November 07, 2023

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

November 02, 2023

Via Benzinga

Why Sarepta Therapeutics Stock Is Crashing Today ↗

October 31, 2023

There's a plot twist with Sarepta's disappointing clinical results.

Via The Motley Fool

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Sarepta Therapeutics to Present at the UBS Biopharma Conference

November 02, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

SRPT earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

November 01, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

What's Going On With Biotech Contract Service Firm Catalent Stock Today? ↗

October 31, 2023

Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.

Via Benzinga

Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss ↗

October 31, 2023

Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to

Via Benzinga

Earnings Scheduled For November 1, 2023 ↗

November 01, 2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Via Benzinga

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 31, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 31, 2023

Via Benzinga

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

October 31, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Near Top of Volume Charts in Tuesday Trading

October 31, 2023

Via Investor Brand Network

Why Are Stocks Down Today? ↗

October 31, 2023

Stocks are down today and investors wondering why have come to the right place as we have an answer to that question!

Via InvestorPlace

BB Stock Alert: What to Know as BlackBerry Announces CEO Departure ↗

October 31, 2023

BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week.

Via InvestorPlace

US Stocks Fall; Pfizer Swings To Q3 Loss ↗

October 31, 2023

U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17....

Via Benzinga

Topics Stocks

Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today? ↗

October 31, 2023

Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial.

Via InvestorPlace

Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2023

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 31, 2023

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...

Via Benzinga

Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 31, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

EMBARKNG On A New Label? New Sarepta DMD Data Leads To Old Debates ↗

October 30, 2023

Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older.

Via Talk Markets

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy ↗

October 30, 2023

The drug didn't meet its primary goal in the pivotal study, but it met secondary measures.

Via Investor's Business Daily

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

October 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock